A Phase II study of cisplatin and cytosine arabinoside for recurrent squamous cell carcinoma of the head and neck

J. I. Bernstein; C. Jacobs; Frederick J Meyers; L. Rich-Goffinet; L. Tanaka

A Phase II study of cisplatin and cytosine arabinoside for recurrent squamous cell carcinoma of the head and neck

J. I. Bernstein, C. Jacobs, Frederick J Meyers, L. Rich-Goffinet, L. Tanaka

Research output: Contribution to journal › Article › peer-review

Abstract

Based on experimental data suggesting synergy between cisplatin and cytosine arabinoside, 17 patients with recurrent squamous cancer of the head and neck were treated with this combination. The response rate was 18% with no complete responses, and the partial responses were of brief duration. There were moderate hematologic and gastrointestinal toxicities and two therapy-related deaths. The study was stopped early because of low reponse. When compared to results reported for cisplatin alone, the combination of cisplatin and cytosine arabinoside offered no clear advantage.

Original language	English (US)
Pages (from-to)	58-60
Number of pages	3
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	9
Issue number	1
State	Published - 1986
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Fingerprint Dive into the research topics of 'A Phase II study of cisplatin and cytosine arabinoside for recurrent squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.

Cite this

@article{cb19405de4bb44d48e0cd8c459c8413f,

title = "A Phase II study of cisplatin and cytosine arabinoside for recurrent squamous cell carcinoma of the head and neck",

abstract = "Based on experimental data suggesting synergy between cisplatin and cytosine arabinoside, 17 patients with recurrent squamous cancer of the head and neck were treated with this combination. The response rate was 18% with no complete responses, and the partial responses were of brief duration. There were moderate hematologic and gastrointestinal toxicities and two therapy-related deaths. The study was stopped early because of low reponse. When compared to results reported for cisplatin alone, the combination of cisplatin and cytosine arabinoside offered no clear advantage.",

author = "Bernstein, {J. I.} and C. Jacobs and Meyers, {Frederick J} and L. Rich-Goffinet and L. Tanaka",

year = "1986",

language = "English (US)",

volume = "9",

pages = "58--60",

journal = "American Journal of Clinical Oncology",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - A Phase II study of cisplatin and cytosine arabinoside for recurrent squamous cell carcinoma of the head and neck

AU - Bernstein, J. I.

AU - Jacobs, C.

AU - Meyers, Frederick J

AU - Rich-Goffinet, L.

AU - Tanaka, L.

PY - 1986

Y1 - 1986

N2 - Based on experimental data suggesting synergy between cisplatin and cytosine arabinoside, 17 patients with recurrent squamous cancer of the head and neck were treated with this combination. The response rate was 18% with no complete responses, and the partial responses were of brief duration. There were moderate hematologic and gastrointestinal toxicities and two therapy-related deaths. The study was stopped early because of low reponse. When compared to results reported for cisplatin alone, the combination of cisplatin and cytosine arabinoside offered no clear advantage.

AB - Based on experimental data suggesting synergy between cisplatin and cytosine arabinoside, 17 patients with recurrent squamous cancer of the head and neck were treated with this combination. The response rate was 18% with no complete responses, and the partial responses were of brief duration. There were moderate hematologic and gastrointestinal toxicities and two therapy-related deaths. The study was stopped early because of low reponse. When compared to results reported for cisplatin alone, the combination of cisplatin and cytosine arabinoside offered no clear advantage.

UR - http://www.scopus.com/inward/record.url?scp=0022628246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022628246&partnerID=8YFLogxK

M3 - Article

C2 - 3953492

AN - SCOPUS:0022628246

VL - 9

SP - 58

EP - 60

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -